Skinvisible Expands Obesity Patent Application for Transdermal Delivery

Skinvisible Pharmaceuticals, Inc. recently announced the filing of a second patent application for its groundbreaking Invisicare technology and its transdermal delivery of obesity and glucose-controlling agents. This new application significantly broadens the scope of the company’s initial patent application titled Transdermal Delivery Composition for Delivery of CB-1 Receptor Antagonists and/or GLP-1 Receptor Agonists, and Method of Delivery, previously announced in May, encompassing a wider range of active ingredients and additional conditions beyond obesity that can benefit from glucose-controlling agents such as diabetes.

The new patent application, titled Transdermal Delivery Composition for Delivery of at Least One Glucose Controlling Agent, and Method of Delivering at Least One Glucose Controlling Agent, represents a substantial leap forward in Skinvisible’s research and development efforts. The Company’s proprietary Invisicare drug delivery technology is at the heart of this innovation, demonstrating its ability to maximize transdermal delivery of various drugs through the skin without the use of a patch or micro-needles.

Key Advantages of Skinvisible’s Transdermal Delivery System Include:

Sustained and substantial transdermal drug delivery over time

Minimal first-pass metabolism, bypassing the gastrointestinal system and liver

Potential reduction in side effects compared to other delivery methods

No needles, no pills, no patches; a transdermal lotion offers a patient-friendly alternative

The obesity treatment market represents a significant opportunity for Skinvisible. According to the Centers for Disease Control and Prevention, obesity affects 42% of all adults in the USA. Furthermore, research by J.P. Morgan projects that by 2030, there could be 30 million GLP-1 users alone in the USA, with the GLP-1 market exceeding $100 billion.

Terry Howlett, CEO of Skinvisible Pharmaceuticals, said “This expanded patent application underscores the groundbreaking development we have undertaken for the transdermal treatment of obesity and other glucose-controlling conditions such as diabetes. Our Invisicare technology allows for significant systemic drug delivery, potentially avoiding the side effects associated with other delivery methods. We have proven that we can deliver these types of molecules for obesity treatment, in stable formulations, and are very excited about the level of transdermal penetration we achieved in our studies.”

Skinvisible continues to develop new formulations incorporating additional obesity/glucose-targeting active ingredients, identified for their superior transdermal penetration and stability. The company’s research focuses on several key drug classes:  GLP-1 Agonists, CB-1 Antagonists and SGLT-2 Inhibitors. These classes of drugs have shown promise in treating obesity and related metabolic disorders, and Skinvisible’s Invisicare transdermal delivery system could potentially enhance their efficacy and patient compliance.

As Skinvisible advances its research and development efforts, the company is actively seeking strategic partnerships with pharmaceutical and biotech companies. The company believes its innovative approach to drug delivery has the potential to revolutionize the obesity treatment market and improve patient outcomes across various therapeutic areas.

Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc., is a pioneering research and development company specializing in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system; Invisicare. This innovative technology provides life-cycle management and distinctive enhancements for both topical and transdermal delivery products.  Invisicare formulated as a lotion or cream, effectively adheres active ingredients to the skin facilitating a controlled release of the active to and/or through the skin and into the blood stream over time. Skinvisible has recently developed formulations for the potential treatment of obesity, along with over forty dermatology-related conditions, including rare skin disorders. For more information, visit